We describe novel rifamycins that have improved activity, compared with rifampin, against clinical isolates of staphylococci and streptococci, with MIC(90)s of 0.008 and 0.0005 microg/ml, respectively. This enhanced antibacterial activity, along with their potential lack of drug-drug interactions, are considerations that suggest the potential of these novel rifamycins in combination therapy to treat serious Gram-positive infections.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/ja.2007.72 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluation of drug-drug interactions of a novel potent FLT3 inhibitor SKLB1028 in healthy subjects.
Clin Transl Sci
November 2024
Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Article Synopsis
- SKLB1028 is a new protein kinase inhibitor being tested to treat a specific type of leukemia (FLT3-ITD mutated acute myeloid leukemia), and its metabolism was studied in clinical trials.* -
- Three studies were conducted with healthy male participants to analyze how other medications (itraconazole, gemfibrozil, and rifampin) affect the metabolism of SKLB1028, focusing on dosage and interaction effects.* -
- Results showed that itraconazole and gemfibrozil increased SKLB1028's exposure in the body, while rifampin decreased it; all drug combinations were well tolerated by participants.*
Ajoene: a natural compound with enhanced antimycobacterial and antibiofilm properties mediated by efflux pump modulation and ROS generation against M. Smegmatis.
Arch Microbiol
November 2024
Centre for Biotechnology, School of Pharmaceutical Sciences, Siksha 'O' Anusandhan (Deemed to be University), Bhubaneswar, Odisha, 751003, India.
Tuberculosis (TB) continues to be a primary worldwide health concern due to relatively ineffective treatments. The prolonged duration of conventional antibiotic therapy warrants innovative approaches to shorten treatment courses. In response to challenges, the study explores potential of Ajoene, a naturally occurring garlic extract-derived compound, for potential TB treatment.
View Article and Find Full Text PDFRifaximin prophylaxis causes resistance to the last-resort antibiotic daptomycin.
Nature
November 2024
Department of Microbiology and Immunology, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
Multidrug-resistant bacterial pathogens like vancomycin-resistant Enterococcus faecium (VREfm) are a critical threat to human health. Daptomycin is a last-resort antibiotic for VREfm infections with a novel mode of action, but for which resistance has been widely reported but is unexplained. Here we show that rifaximin, an unrelated antibiotic used prophylactically to prevent hepatic encephalopathy in patients with liver disease, causes cross-resistance to daptomycin in VREfm.
View Article and Find Full Text PDFA novel dual probe-based method for mutation detection using isothermal amplification.
PLoS One
October 2024
Revvity, Inc., Waltham, MA, United States of America.
Cost efficient and rapid detection tools to detect mutations especially those linked to drug-resistance are important to address concerns of the rising multi-drug resistance infections. Here we integrated dual probes, namely a calibrator probe and an indicator probe, into isothermal amplification detection system. These two probes are designed to bind distinct regions on the same amplicon to determine the presence or absence of mutation.
View Article and Find Full Text PDFDegarelix limits the survival of mycobacteria and granuloma formation.
Microb Pathog
December 2024
Shanghai Key Laboratory of Tuberculosis, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, 200433, China; School of Public Health, The Key Laboratory of Environmental Pollution Monitoring and Disease Control, Ministry of Education, Guizhou Medical University, Guiyang, 561113, China. Electronic address:
Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb) infection, is a serious health hazard, characterized by tuberculous granuloma formation, which may facilitate bacterial survival. At the same time, the identification of multidrug-resistant and extremely drug-resistant Mtb strains, and the progressive accumulation of mutations in biological targets of frontline antimicrobials, has made TB treatments more difficult. Therefore, new and rapid drug development for TB is warranted.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!